ESPR Esperion Therapeutics, Inc.

8-K Current Report

Filed: March 10, 2026

Health Care

Pharmaceutical Preparations

Esperion Therapeutics, Inc. (ESPR) 8-K current report filed with SEC EDGAR on March 10, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q4 and full-year 2025 financial results announced March 10, 2026
• Full details in Exhibit 99.1 press release — key figures not disclosed in this filing item

Other Esperion Therapeutics, Inc. 8-K Filings

8-K Mar 3, 2026

Get deeper insights on Esperion Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.